Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?

Key Points Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market. Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sales. Novo Nordisk's deep pipeline makes it likely to remain a leader in this space over the medium term. 10 stocks we like better than Novo Nordisk › Novo Nordisk 's (NYSE:NVO) semaglutide, sold under the brand names Wegovy and Ozempic, is one of the world's best-selling compounds. Not that this has allowed the company to perform in line with broader equities over the past two years. The pharmaceutical giant has lost a little over 60% of its value over this period. Can Novo Nordisk bounce back?